Advances on biological characteristics of PXR and its effect  on drug metabolism

Abstract

Abstract: The nuclear pregnane X receptor(PXR) is a kind of hormones and environmental receptors and is widely distributed in organism.PXR not only involved in the metabolism of energy,cholesterol,bile acids and other substances as well as regulation of the inflammatory response,and also regulates phase Ⅰ,Ⅱ phase drug metabolizing enzymes and the related the expression of drug transporters. It is important for the body to maintain a variety of physiological functions such as cell proliferation and differentiation, growth and development, metabolism, homeostasis.This paper reviewed the PXR structure and function, biological effects and the regulation of drug-metabolizing enzymes and drug transporters.

Key words: Nuclear receptor, PXR, Drug metabolism

CLC Number:

R968

CHEN Qun, XU Zhe, SUN Hua, XIE Hai-tang. Advances on biological characteristics of PXR and its effect on drug metabolism[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(3): 241-246.

References

[1] Markov GV, Laudet V. Origin and evolution of the ligand-binding ability of nuclear receptors[J].Mol Cell Endocrinol, 2011,334(1/2):21-30.
[2] Merk D, Schubert-Zsilavecz M. Nuclear receptors as pharmaceutical targets:rise of FXR and rebirth of PPAR[J] ? Future Med Chem, 2012,4(5):587-588.
[3] Swanson H, Wada T, Xie W, et al. Role of Nuclear Receptors in Lipid Dysfunction and Obesity-related Diseases[J]. Drug Metab Dispos, 2013,41(1):1-11.
[4] Li L, Stanton JD, Tolson AH, et al. Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways[J]. Pharm Res, 2009,26(4):872-882.
[5] Tirona RG. Molecular mechanisms of drug transporter regulation[J]. Handb Exp Pharmacol, 2011,(201):373-402.
[6] Kobayashi K, Saito K, Takagi S, et al. Ligand-Dependent Assembly of Pregnane X Receptor, Constitutive Androstane Receptor and Liver X Receptor is Applicable to Identify Ligands[J]. Drug Metab Lett,2010,4(2):88-94.
[7] Kliewer SA, Moore JT, Wade L, et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway[J]. Cell, 1998,92(1):73-82.
[8] Koyano S, Kurose K, Saito Y, et al. Functional characterization of four naturally occurring variants of human pregnane X receptor (PXR): one variant causes dramatic loss of both DNA binding activity and the transactivation of the CYP3A4 promoter/enhancer region[J]. Drug Metab Dispos,2004,32(1):149-154.
[9] Squires EJ, Sueyoshi T, Negishi M. Cytoplasmic localization of pregnane X receptor and ligand-dependent nuclear translocation in mouse liver[J]. J Biol Chem, 2004,279(47): 49307-49314.
[10] Kawana K, Ikuta T, Kobayashi Y, et al.Molecular mechanism of nuclear translocation of an orphan nuclear receptor, SXR[J]. Mol Pharmacol, 2003,63(3):524-531.
[11] Ekins S, Kortagere S, Iyer M, et al.Challenges predicting ligand-receptor interactions of promiscuous proteins: the nuclear receptor PXR[J]. PLoS Comput Biol,2009,5(12):e1000594.
[12] Ngan CH, Beglov D, Rudnitskaya AN, et al.The structural basis of pregnane X receptor binding promiscuity[J]. Biochemistry, 2009, 48(48):11572-11581.
[13] Cheng J, Ma X, Gonzalez FJ. Pregnane X receptor- and CYP3A4-humanized mouse models and their applications[J]. Br J Pharmacol, 2011,163(3):461-468.
[14] Cheng J, Ma X, Krausz KW, et al. Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity[J]. Drug Metab Dispos, 2009,37(8):1611-1621.
[15] Buler M, Aatsinki SM, Skoumal R, et al. Energy sensing factors PGC-1α and SIRT1 modulate PXR expression and function[J]. Biochem Pharmacol, 2011,82(12):2008-2015.
[16] Buler M, Aatsinki SM, Skoumal R, et al. Energy sensing factors PGC-1α and SIRT1 modulate PXR expression and function[J]. Biochem Pharmacol, 2011,82(12):2008-2015.
[17] Zhai Y, Wada T, Zhang B, et al. A functional cross-talk between liver X receptor-α and constitutive androstane receptor links lipogenesis and xenobiotic responses[J]. Mol Pharmacol, 2010,78(4):666-674.
[18] Gao J, Xie W. Targeting xenobiotic receptors PXR and CAR for metabolic diseases[J]. Trends Pharmacol Sci, 2012,33(10):552-558.
[19] Yacovino LL, Aleksunes LM. Renal efflux transporter expression in pregnant mice with Type I diabetes[J]. Toxicol Lett, 2012,211(3):304-311.
[20] Ihunnah CA, Jiang M, Xie W. Nuclear receptor PXR, transcriptional circuits and metabolic relevance[J]. Biochim Biophys Acta, 2011,1812(8):956-963.
[21] Hebanowska A. Mechanisms of bile acid biosynthesis regulation-autoregulation by bile acids[J]. Postepy Biochem, 2011,57(3):314-323.
[22] Ma X, Idle JR, Gonzalez FJ. The pregnane X receptor: from bench to bedside[J].Expert Opin Drug Metab Toxicol, 2008,4(7):895-908.
[23] Xie W, Radominska-Pandya A, Shi Y, et al.An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids[J]. Proc Natl Acad Sci USA, 2001,98(6):3375-3380.
[24] Wang YG, Zhou JM, Ma ZC, et al.Pregnane X receptor mediated-transcription regulation of CYP3A by glycyrrhizin: A possible mechanism for its hepatoprotective property against lithocholic acid-induced injury[J]. Chem Biol Interact, 2012,200(1):11-20.
[25] Echchgadda I, Song CS, Oh T, et al. The xenobiotic-sensing nuclear receptors pregnane X receptor, constitutive androstane receptor, and orphan nuclear receptor hepatocyte nuclear factor 4alpha in the regulation of human steroid-/bile acid-sulfotransferase[J]. Mol Endocrinol, 2007,21(9):2099-2111.
[26] Weerachayaphorn J, Mennone A, Soroka CJ, et al.Nuclear factor-E2-related factor 2 is a major determinant of bile acid homeostasis in the liver and intestine[J]. Am J Physiol Gastrointest Liver Physiol, 2012,302(9):G925-36.
[27] Zhou C, Tabb MM, Nelson EL, et al. Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation[J]. J Clin Invest, 2006,116(8):2280-2289.
[28] Fiorucci S, Distrutti E, Bifulco G, et al. Marine sponge steroids as nuclear receptor ligands[J]. Trends Pharmacol Sci, 2012,33(11):591-601.
[29] Dou W, Mukherjee S, Li H, et al.Alleviation of gut inflammation by Cdx2/Pxr pathway in a mouse model of chemical colitis[J]. PLoS One,2012,7(7):e36075.
[30] Zhai Y, Pai HV, Zhou J, et al. Activation of pregnane X receptor disrupts glucocorticoid and mineralocorticoid homeostasis[J]. Mol Endocrinol, 2007,21(1):138-147.
[31] Zhang B, Cheng Q, Ou Z, et al.Pregnane X receptor as a therapeutic target to inhibit androgen activity[J].Endocrinology, 2010,151(12):5721-5729.
[32] Wang T, Ma X, Krausz KW, et al.Role of pregnane X receptor in control of all-trans retinoic acid (ATRA) metabolism and its potential contribution to ATRA resistance[J]. J Pharmacol Exp Ther, 2008,324(2):674-684.
[33] Ross PK, Woods CG, Bradford BU, et al.Time-course comparison of xenobiotic activators of CAR and PPARalpha in mouse liver[J]. Toxicol Appl Pharmacol, 2009,235(2):199-207.
[34] Ross J, Plummer SM, Rode A, et al.Human constitutive androstane receptor (CAR) and pregnane X receptor (PXR) support the hypertrophic but not the hyperplastic response to the murine nongenotoxic hepatocarcinogens phenobarbital and chlordane in vivo[J].Toxicol Sci, 2010,116(2):452-466.
[35] Purnapatre K, Khattar SK, Saini KS. Cytochrome P450s in the development of target-based anticancer drugs[J]. Cancer Lett, 2008,259(1):1-15.
[36] Tojima H, Kakizaki S, Yamazaki Y, et al. Ligand dependent hepatic gene expression profiles of nuclear receptors CAR and PXR[J]. Toxicol Lett, 2012,212(3):288-297.
[37] Kishida T, Muto S, Hayashi M, et al.Strain differences in hepatic cytochrome P450 1A and 3A expression between Sprague-Dawley and Wistar rats[J]. J Toxicol Sci, 2008,33(4):447-457.
[38] Mueller SO, Fery Y, Tuschl G, et al. Species-specific activation of nuclear receptors correlates with the response of liver drug metabolizing enzymes to EMD 392949 in vitro[J]. Toxicol Lett, 2010,193(1):120-123.
[39] Marino M, di Masi A, Trezza V, et al.Xenosensors CAR and PXR at work: impact on statin metabolism[J]. Curr Drug Metab,2011,12(3):300-311.
[40] Kacevska M, Downes MR, Sharma R, et al.Extrahepatic cancer suppresses nuclear receptor-regulated drug metabolism[J]. Clin Cancer Res, 2011,17(10):3170-3180.
[41] Han EH, Kim HG, Choi JH, et al.Capsaicin induces CYP3A4 expression via pregnane X receptor and CCAAT/enhancer-binding protein β activation[J].Mol Nutr Food Res, 2012,56(5):797-809.
[42] Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/transport by xenobiotics[J]. Arch Pharm Res, 2005, 28(3):249-268.
[43] Wang H, LeCluyse EL. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes[J]. Clin Pharmacokinet, 2003,42(15):1331-1357.
[44] Bolt HM.Rifampicin, a keystone inducer of drug metabolism: from Herbert Remmer's pioneering ideas to modern concepts[J].Drug Metab Rev,2004,36(3/4):497-509.
[45] Rigalli JP, Ruiz ML, Perdomo VG,et al. Pregnane X receptor mediates the induction of P-glycoprotein by spironolactone in HepG2 cells[J].Toxicology,2011,285(1/2):18-24.
[46] Rulcova A,Prokopova I,Krausova L,et al.Stereoselective interactions of warfarin enantiomers with the pregnane X nuclear receptor in gene regulation of major drug-metabolizing cytochrome P450 enzymes[J].J Thromb Haemost,2010,8(12):2708-2717.
[47] Harmsen S, Meijerman I, Beijnen JH,et al.Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor[J].Cancer Chemother Pharmacol,2009,64(1):35-43.
[48] Dvorak Z.Drug-drug interactions by azole antifungals: Beyond a dogma of CYP3A4 enzyme activity inhibition[J].Toxicol Lett,2011,202(2):129-132.
[49] Ooi JP, Kuroyanagi M, Sulaiman SF,et al.Andrographolide and 14-deoxy-11, 12-didehydroandrographolide inhibit cytochrome P450s in HepG2 hepatoma cells[J].Life Sci,2011,88(9/10):447-454.
[50] Honorat M, Mesnier A, Di Pietro A,et al.Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells[J].Biochem Biophys Res Commun,2008,375(3):308-314.
[51] Wang H, Li H, Moore LB, et al.The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor[J].Mol Endocrinol,2008,22(4):838-857.
[52] Lim YP, Ma CY,Liu CL,et al. Sesamin: A Naturally Occurring Lignan Inhibits CYP3A4 by Antagonizing the Pregnane X Receptor Activation[J].Evid Based Complement Alternat Med, 2012,2012:242810.
[53] Ronaldson PT, Davis TP. Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery[J]. Ther Deliv,2011,2(8):1015-1041.
[54] Abbott NJ, Patabendige AA, Dolman DE, et al. Structure and function of the blood-brain barrier[J]. Neurobiol Dis, 2010,37(1):13-25.
[55] Hartz AM, Bauer B. Regulation of ABC transporters at the blood-brain barrier: new targets for CNS therapy[J]. Mol Interv,2010,10(5):293-304.
[56] Miller DS. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier[J]. Trends Pharmacol Sci,2010,31(6):246-254.
[57] Ott M, Fricker G, Bauer B. Pregnane X receptor (PXR) regulates P-glycoprotein at the blood-brain barrier: functional similarities between pig and human PXR[J]. J Pharmacol Exp Ther,2009,329(1):141-149.
[58] Ott M, Fricker G, Bauer B. Pregnane X receptor (PXR) regulates P-glycoprotein at the blood-brain barrier: functional similarities between pig and human PXR[J]. J Pharmacol Exp Ther,2009,329(1):141-149.
[59] Gahir SS, Piquette-Miller M. Gestational and pregnane X receptor-mediated regulation of placental ATP-binding cassette drug transporters in mice[J]. Drug Metab Dispos,2011,39(3):465-471.

Advances on biological characteristics of PXR and its effect on drug metabolism

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHANG Yuanjin, HUANG Shengbo, LIU Jie, WANG Xin. Construction and application of innovation gene-edited rats and intestinal 3D organoids models in drug metabolism and pharmacokinetics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 914-922.
[2]	CHEN Hongzhu, LIU Jianming, ZHOU Fang, JIA Yuanwei, WANG Guangji, ZHANG Jingwei. Effect and mechanism of endogenous metabolism on drug metabolism and disposition [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 580-588.
[3]	XIN Huawen, YANG Yan. Association of synergistic effects of Wuzhi capsules on tacrolimus and PXR polymorphisms [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(10): 1138-1144.
[4]	TANG Xia, XIN Hua-wen, LI Wei-liang, OUYANG Meng. Study of the effects of Berberine on CYP3A4 and P-gp in HepG2 cells and its mechanism in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(1): 7-13.
[5]	LV Pei-yu, YUAN Hong, ZHOU Hong-hao, OUYANG Dong-sheng. Genetic variation of cytochrome P450 oxidase and personalized medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(11): 1281-1287.
[6]	SHI Shu-ya, WANG Lian-sheng. Progress in research of phase Ⅱ metabolisms and their enzymes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(1): 82-89.
[7]	ZHANG Yi-wen, BAO Mei-hua, ZHOU Li-hua, ZHOU Hong-hao. Function of pregnane X receptor in drug mechanism and research progress [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(10): 1169-1174.
[8]	HU Lei, GAO Li-chen, ZHUO Wei, ZHOU Hong-hao, FAN Lan. Advances in pharmacogenomics of cytochrome P450 oxidoreductase [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(7): 821-827.
[9]	LI Yun, HE Fang, ZENG Cai-wen, LIU Lin-lin, XIA Chun-hua. Effect of CYP2C9, CYP2C19, CYP3A4 polymorphism on metabolism of sulfonyluea antidiabetic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(5): 582-587.
[10]	GAO Li-chen, ZHANG Wei, LIU Zhao-qian, FAN Lan, ZHOU Hong-hao. Progress in clinical herb-drug interactions mediated by drug metabolism- related genes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(3): 346-351.
[11]	HE Fang, ZENG Cai-wen, XIA Chun-hua, XIONG Yu-qing. Regulation of nuclear receptors on cytochrome P450 enzymes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(10): 1195-1200.
[12]	XIONG Dan, XIONG Yu-qing. Polymorphism of CYP2D6 gene and the influence on the metabolism of metoprolol [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(9): 1059-1064.
[13]	ZHANG Song-bo, DUAN Juan, ZHOU Hong-hao. Effects of regular consumption of RRR-α-tocopherol on the activity of P-gp in vivo [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(5): 545-548.
[14]	HAN Lu, LIU Jie. Polymorphism of CYP2D6 and the influence to the drug metabolism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(1): 105-110.
[15]	YAN Fei, XIA Chun-hua, XIONG Yu-qing. Effect of CYP2C19 genetic polymorphism on drug metabolism and individualized therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(8): 949-953.